In Wednesday’s Wall Street session, Allogene Therapeutics Inc (NASDAQ:ALLO) shares traded at $0.95, down -15.68% from the previous session.
ALLO stock price is now -38.93% away from the 50-day moving average and -56.08% away from the 200-day moving average. The market capitalization of the company currently stands at $208.38M.
On March 14, 2025, Citizens JMP Upgraded its previous ‘Mkt Perform’ rating to ‘Mkt Outperform’ on the stock keeping its target price maintained at $5, while ‘Oppenheimer’ rates the stock as ‘Outperform’
In other news, Yoshiyama Annie, SVP, Finance sold 9,601 shares of the company’s stock on Apr 21 ’25. The stock was sold for $13,537 at an average price of $1.41. Upon completion of the transaction, the SVP, Finance now directly owns 130,663 shares in the company, valued at $0.12 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 21 ’25, Officer Yoshiyama Annie bought 9,601 shares of the business’s stock. A total of $13,537 was incurred on buying the stock at an average price of $1.41. A total of 34.52% of the company’s stock is owned by insiders.
During the past 12 months, Allogene Therapeutics Inc has had a low of $1.06 and a high of $3.78. As of last week, the company has a debt-to-equity ratio of 0.23, a current ratio of 9.71, and a quick ratio of 9.71. The fifty day moving average price for ALLO is $1.5602 and a two-hundred day moving average price translates $2.16975 for the stock.
The latest earnings results from Allogene Therapeutics Inc (NASDAQ: ALLO) was released for 2025-03-31.
